Table 1 Baseline characteristics comparison on patients in the modeling group and the validation groupa
Variables | Validation group (n = 562) | Modeling group (n = 1313) | p |
|---|---|---|---|
gender, n (%) | Â | Â | 0.315 |
 female | 172 (31) | 370 (28) |  |
 male | 390 (69) | 943 (72) |  |
age, (years) | 67 (53, 79) | 68 (54, 79) | 0.13 |
NSTEMI | Â | Â | 0.087 |
 no | 444 (79) | 1083 (82) |  |
 yes | 118 (21) | 230 (18) |  |
heart failure | 27(4.8) | 70(5.3) | 0.637 |
systolic blood pressure | Â | Â | 0.6 |
 90-140 mmHg | 328 (58) | 759 (58) |  |
  < 90 mmHg | 14 (2) | 24 (2) |  |
  > 140 mmHg | 220 (39) | 530 (40) |  |
heart rate, (beats/minute) | 78.5 (69, 90) | 79 (68, 90) | 0.702 |
PCI | Â | Â | 0.869 |
 no | 256 (46) | 591 (45) |  |
 yes | 306 (54) | 722 (55) |  |
troponin T, (ng/mL) | 0.23 (0.06, 0.85) | 0.21 (0.05, 0.86) | 0.512 |
creatine kinase isoenzyme | Â | Â | 0.848 |
  < 25 ng/ml | 252 (45) | 603 (46) |  |
 25-150 ng/ml | 264 (47) | 611 (47) |  |
  > 150 ng/ml | 46 (8) | 99 (8) |  |
D-Dimer, mg/L | Â | Â | 0.939 |
  < 2 mg/L | 488 (87) | 1140 (87) |  |
 2–5 mg/L | 53 (9) | 120 (9) |  |
  > 5 mg/L | 21 (4) | 53 (4) |  |
pro-brain natriuretic peptide | Â | Â | 0.721 |
  < 500 ng/L | 249 (44) | 593 (45) |  |
 500-15,000 ng/L | 283 (50) | 640 (49) |  |
  > 15,000 ng/L | 30 (5) | 80 (6) |  |
aspartate aminotransferase, (U/L) | 234 (192, 342.75) | 237 (192, 332) | 0.801 |
creatinine | Â | Â | 0.915 |
  < 100 μmol/L | 453 (81) | 1056 (80) |  |
 100-200 μmol/L | 94 (17) | 216 (16) |  |
 201-400 μmol/L | 12 (2) | 29 (2) |  |
  > 400 μmol/L | 3 (1) | 12 (1) |  |
C-reactive protein | Â | Â | 0.06 |
  < 30 mg/L | 481 (86) | 1071 (82) |  |
 30-80 mg/L | 51 (9) | 169 (13) |  |
  > 80 mg/L | 30 (5) | 73 (6) |  |
hematocrit | Â | Â | 0.827 |
 0.3–0.45 L/L | 399 (71) | 914 (70) |  |
  <  0.3 L/L | 29 (5) | 69 (5) |  |
  > 0.45 L/L | 134 (24) | 330 (25) |  |
white blood cell (× 109/L) | 9.52 (7.45, 11.93) | 9.42 (7.1, 11.93) | 0.402 |
platelets (×109/L) | 211.5 (171.25, 254) | 209 (171, 255) | 0.464 |
left ventricular ejection fraction, (%) | 57 (50, 63) | 57 (48, 63) | 0.719 |